Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults.
OBJECTIVE
To investigate the effects of preoperative brimonidine-purite 0.15% instillation on intraoperative bleeding and postoperative subconjunctival hemorrhage during strabismus surgery in adult patients.


METHODS
Randomized comparative interventional case series.


METHODS
One hundred and eighteen eyes of 90 consecutive adult patients were instilled with either a single drop of brimonidine-purite 0.15% (42 eyes), phenylephrine 1% (38 eyes), or sodium hyaluronate 0.1% (38 eyes) 15 minutes prior to strabismus surgery. Intraoperative bleeding and postoperative subconjunctival hemorrhage were graded on a scale of one to three. The scores were compared among the study groups.


RESULTS
Scores of the intraoperative bleeding and the postoperative subconjunctival hemorrhage of the treatment groups were significantly less than that of the control group (P < .001). The scores of the brimonidine group were similar to those of the phenylephrine group (intraoperative bleeding score, P = .405; subconjunctival hemorrhage score, P = .722).


CONCLUSIONS
Topical brimonidine administration before strabismus surgery may reduce intraoperative bleeding and postoperative subconjunctival hemorrhage in adult patients.
Hong
Samin
S
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Kim
Chan Yun
CY
Seong
Gong Je
GJ
Han
Sueng-Han
SH
D000287:Administration, Topical; D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000328:Adult; D000068438:Brimonidine Tartrate; D003229:Conjunctival Diseases / Q000517:prevention & control*; D004311:Double-Blind Method; D005130:Eye Hemorrhage / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage; D008297:Male; D009801:Oculomotor Muscles / Q000601:surgery; D010656:Phenylephrine / Q000008:administration & dosage; D011292:Premedication; D011810:Quinoxalines / Q000627:therapeutic use*; D013285:Strabismus / Q000601:surgery
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D011810:Quinoxalines; D010656:Phenylephrine; D000068438:Brimonidine Tartrate; D006820:Hyaluronic Acid